Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan

por Uhara, H., Kiyohara, Y., Tsuda, A., Takata, M., Yamazaki, N.
Publicado 2017

Status of the INS SF-ECR ion source

por Ohshiro, Y, Yamazaki, T, Fujita, M, Yamazaki, N, Nishiguchi, M, Muto, H
Publicado 1995

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses

por Omata, W., Tsutsumida, A., Namikawa, K., Takahashi, A., Oashi, K., Yamazaki, N.
Publicado 2017

Low-energy RI beam separator CRIB

por Teranishi, T, Kubono, S, Yanagisawa, Y, Shimoura, S, Mizoi, Y, Notani, M, Michimasa, S, Ue, K, Watanabe, S, Yamazaki, N, Oshiro, M, Kishida, T, Kato, S
Publicado 2001

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma

por Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., Tokudome, T.
Publicado 2015

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

por Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Publicado 2015

Low-energy radioisotope beam separator CRIB

por Yanagisawa, Y, Kubono, S, Teranishi, T, Ue, K, Michimasa, S, Notani, M, He, J J, Ohshiro, Y, Shimoura, S, Watanabe, S, Yamazaki, N, Iwazaki, H, Kato, S, Kishida, T, Morikawa, T, Mizoi, Y
Publicado 2004

Nuclear astrophysics project with a new low-energy RIB separator CRIB: Study of a critical stellar reaction $^{15}O(alpha,gamma)^{19}Ne$

por Kubono, S, Michimasa, S, Teranishi, T, Yanagisawa, Y, Fülöp, Z, Liu, X, Kumagai, K, Abe, K, Yun, C C, Watanabe, S, Yamazaki, N, Ohshiro, Y, Kurokawa, M, Strasser, P, Hahn, K I, Kishida, T, Imai, N, Kato, S, Fuchi, Y, Tanaka, M H
Publicado 2001

Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, mu...

por Nakamura, Y., Namikawa, K., Yoshikawa, S., Kiniwa, Y., Maekawa, T., Yamasaki, O., Isei, T., Matsushita, S., Nomura, M., Nakai, Y., Fukushima, S., Saito, S., Takenouchi, T., Tanaka, R., Kato, H., Otsuka, A., Matsuya, T., Baba, N., Nagase, K., Inozume, T., Fujimoto, N., Kuwatsuka, Y., Onishi, M., Kaneko, T., Onuma, T., Umeda, Y., Ogata, D., Takahashi, A., Otsuka, M., Teramoto, Y., Yamazaki, N.
Publicado 2021